IBSA USA
Rajesh Yerramilli is a seasoned finance and business professional with extensive experience in various roles across the healthcare and consulting sectors. Currently serving as Finance Manager at IBSA USA since February 2024, previous positions include Senior Business Analyst at Genentech and Consultant at IQVIA. Rajesh also held leadership roles as Project Leader at Axtria - Ingenious Insights and Consulting Specialist at Infosys. Additional experience includes Senior Consultant roles at CGI and Cumberland, alongside earlier positions at ConvaTec and Business Intelligence Squared, LLC, where responsibilities encompassed complex analyses, contract administration, and operational enhancements. Rajesh holds a Bachelor of Science in Business Administration with concentrations in Accounting and Computer Information Systems from Rider University.
This person is not in any teams
IBSA USA
IBSA USA is the subsidiary of IBSA Group, the largest privately owned pharmaceutical company in Switzerland. IBSA is committed to improving patient quality of life through research, innovation, and the development of effective drugs and cutting-edge technologies. IBSA USA markets two unique levothyroxine formulations in the U.S. for the treatment of hypothyroidism: Tirosint® (levothyroxine sodium) capsules and Tirosint®-SOL (levothyroxine sodium) oral solution. IBSA also markets Licart™ (diclofenac epolamine) topical system 1.3%, the only once-a-day topical nonsteroidal anti-inflammatory (NSAID) available in the U.S. to treat acute pain due to minor strains, sprains, and contusions. IBSA is focused on the health and well-being of patients and driven by the desire to bring therapeutic alternatives to as many people as possible. IBSA Group bases its philosophy on four sustainable pillars: Person, Innovation, Quality, and Responsibility. For more information about Tirosint, Tirosint-SOL, or Licart, including Full Prescribing Information, go to each brand’s respective website.